ADAM10 Recombinant Monoclonal Antibody

1. SNHG20 could function as an oncogenic long non-coding RNA by regulating miR-140-5p-ADAM10 axis and MEK/ERK signaling pathway in cervical cancer. PMID: 29604594
2. restoration of ADAM10 expression partially reversed the effects of miR152 on cell proliferation and apoptosis in rheumatoid arthritisfibroblastlike synoviocytes. PMID: 29693139
3. Mechanisms underlying ADAM10 downregulation by miR-140-5p and suggests that dysfunctional regulation of ADAM10 expression is exacerbated by AD-related neurotoxic effects. PMID: 29253717
4. elevated expression of ADAM10 was associated with the pathogenesis and development of immune thrombocytopenia PMID: 29223855
5. Report overexpression of ADAM10 in oral squamous cell carcinomas, especially in OSCC with metastasis. PMID: 29895129
6. High ADAM10 expression is associated with meningococcal purpura fulminans. PMID: 29630665
7. The findings of the present study suggested that miR320a may function as a tumor suppressor in GC progression and potential therapeutic strategies for GC may be based on the miR320a/ADAM10 axis. PMID: 29152656
8. Insulin-like growth factor-1 activates different catalytic subunits p110 of PI3K in a cell-type-dependent manner to induce lipogenesis-dependent epithelial-mesenchymal transition through the regulation of ADAM10 and ADAM17. PMID: 28819788
9. mechanistic experiments revealed that ADAM10-RNAi resulted in an increase in E-cadherin and a decrease in N-cadherin and vimentin expression. Our study implies that high expression of ADAM10 promotes the proliferation and migration of hypopharyngeal squamous cell carcinoma (HSCC). These findings may help to provide a method for treatment of HSCC PMID: 28656294
10. Notch is ligand activated and undergoes DTX4-mediated ubiquitylation and bilateral endocytosis before ADAM10 processing PMID: 28611181
11. therapies against ADAM10 and ADAM17 may promote cancer stem cell migration away from the tumourigenic niche resulting in a differentiated phenotype that is more susceptible to treatment. PMID: 27541285
12. Presence of anti-ADAM10 auto-Antibodies seems to reflect the increased tumor expression of the immunogenic immature-ADAM10 in a group of Colorectal cancer patients, and is associated with a favourable prognosis in patients at stage III of the disease. PMID: 27517630
13. ADAM10 and ADAM17 are the best characterized members of the ADAM (A Disintegrin and Metalloproteinase) - family of transmembrane proteases. Both are involved diverse physiological and pathophysiological processes.For ADAM17 phosphatidylserine exposure is required to then induce its shedding function. PMID: 28624437
14. A better understanding of the regulatory mechanisms controlling the expression, subcellular localization and activity of ADAM10 will likely uncover suitable drug targets which will allow a more specific and fine-tuned modulation of its proteolytic activity PMID: 28624438
15. In the present study, the authors show that deletion of a triple serine (3S) motif (Ser-359 to Ser-361) adjacent to the cleavage site is sufficient to prevent IL-6R cleavage by ADAM17, but not ADAM10. We find that the impaired shedding is caused by the reduced distance between the cleavage site and the plasma membrane. PMID: 27151651
16. Here, I review some of the proposed functions of ADAM10 associated with intestinal crypt homeostasis and tumorigenesis within the gastrointestinal tract in vivo. PMID: 28739265
17. Study reports the structure of the ADAM10 ectodomain, providing fundamental insights into how substrate selectivity and regulation of catalytic activity is achieved in this important representative of the ADAM family of metalloproteases. PMID: 29224781
18. Data suggest that ADAM10 associates directly with all members of a subgroup of tetraspanins having eight cysteines in the large extracellular domain ('TspanC8'): Tspan5, Tspan10, Tspan14, Tspan15, Tspan17, and Tspan33. [REVIEW] PMID: 28687716
19. Results found ADAM10 expression under the regulation of MIR-655 which binds the 3'-UTR of ADAM10 mediating the progression of hepatocellular carcinoma. PMID: 27259866
20. Data suggest that activation of the metalloproteinase ADAM10 by signal peptide peptidase-like 3 (SPPL3) triggered by mutant BRAF(V600E) was a critical transformation event. PMID: 28292959
21. The ADAM17 messenger RNA (mRNA) and protein levels were significantly higher in the inferior turbinate than in nasal polyps (p < 0.05). The ADAM10 mRNA and protein levels did not differ significantly between NPs and inferior turbinates (p > 0.05). ADAM10 and ADAM17 were expressed primarily in inflammatory cells, submucosal glandular cells, and lining epithelial cells. PMID: 27012683
22. study confirms the importance of ICOSL shedding in ICOS/ICOSL function and expression and it identifies ADAM10 as the most important sheddase for controlling ICOSL levels PMID: 28814605
23. Inhibition of ADAM10 suppressed the expansion of NK cells and reduced the expression of CD16. PMID: 28982863
24. Platelet ADAM10 protein expression in patients with AD [Alzheimer's Disease] was positively influenced by serotoninergic medication PMID: 26555131
25. Tspan3 is a central endocytic membrane component regulating the expression of ADAM10, presenilin and the amyloid precursor protein. PMID: 27818272
26. Endothelial Tspan5- and Tspan17-ADAM10 complexes may regulate inflammation by maintaining normal VE-cadherin expression and promoting T lymphocyte transmigration. PMID: 28600292
27. Regulation of ADAM10 by the TspanC8 subgroup of tetraspanins, namely Tspan5, 10, 14, 15, 17 and 33 is reviewed. PMID: 28620033
28. active ADAM10 form marks cancer stem-like cells with active Notch signaling, known to mediate chemoresistance. PMID: 27503072
29. Data show that tetraspanin 33 (tspan33) is an early activation marker, and that disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) protein expression does not correlate with Tspan33 expression in B cells. PMID: 28449222
30. High ADAM10 expression is associated with metastasis of hepatocellular carcinoma. PMID: 28184920
31. The dysregulation of ADAM10, Fas and FasL could be useful indicators of the progression and severity of OSCC. PMID: 27628319
32. 1,25D3 causes ectodomain shedding of TLR4 and thereby decreases the responsiveness of cells to LPS. ADAM10, activated by extracellular Ca2+ influx, was implicated in the ectodomain cleavage of TLR4. PMID: 28427048
33. The overexpression of MTERF4 induced a significant increase in the levels of APP protein and secreted Abeta 42 in HEK293-APPswe cells compared with control cells these results suggest that MTERF4 promotes the amyloidogenic processing of APP by inhibiting ADAM10 in HEK293-APPswe cells; therefore, MTERF4 may play an important role in the pathogenesis of Alzheimer's disease. PMID: 27894840
34. Pre-incubation with simvastatin prior to treatment with IL-1beta + Oncostatin M decreased the level of CD44 fragmentation, decreased the proportion of CD44 that transits into the lipid raft fractions, decreased ADAM10 activity and diminished the interaction between CD44 and ADAM10. PMID: 27242325
35. ADAM17 and ADAM10 cleave Nectin-4 and release soluble Nectin-4 (sN4). PMID: 28232483
36. Data show that mononuclear leukocytes (PBMC) AXL receptor tyrosine kinase (Axl) is rescued by combined matrix metalloproteases ADAM10 and TACE (ADAM17) inhibition. PMID: 27237127
37. we found that ADAM10 expression was associated with a more rapid metastatic progression confirming its role in uveal melanoma metastasis. PMID: 27546281
38. the TLR4/Gal-1 signaling pathway regulates lactate-mediated EMT processes through the activation of ADAM10 and ADAM17 in colon cancer cells. PMID: 27837433
39. Studies demonstrate a role for ADAM10 in the ectodomain shedding of LRP1 in the brain and the clearance of Abeta across the blood-brain barrier, which may provide a novel strategy for attenuating Abeta accumulation in the AD brain PMID: 27503326
40. In response to trastuzumab, both HER3 and the metalloprotease ADAM10 are simultaneously upregulated. The proteolytic activity of the latter then releases the HER3 ligand heregulin from the cell surface to activate HER3 and confer resistance to trastuzumab by inducing compensatory growth factor receptor signaling. PMID: 26863569
41. Active ADAM10 promotes the carcinogenesis, invasion, metastasis and proliferation of ESCC and controls invasion and metastasis at least in part through the shedding of E-cadherin activity. PMID: 26986985
42. We now show that ADAM10 is critical for alpha-hemolysin-mediated activation of the NLRP3 inflammasome in human monocytes as siRNA knockdown or chemical blockade of ADAM10-alpha-hemolysin interaction leads to diminished inflammasome activation and cell death by reducing the available ADAM10 on the cell surface. PMID: 27043625
43. ADAM10 was overexpressed in the posterior band of sections from some patients with temporomandibular joint disk disorders. PMID: 26947053
44. ADAM10 activity contributes to house dust mite-induced shedding of chemokines, including CCL20 PMID: 26296735
45. The results of this study demonistrated that age-dependent increase in ADAM10 levels and activity in platelets. PMID: 26757187
46. higher expression levels in the allergic nasal mucosa PMID: 26250527
47. The production of ADAM10-positive microvesicles from smoke-exposed neutrophils provides a novel molecular mechanism for the vastly accelerated risk of AAA in smokers. PMID: 26422658
48. activated microRNA-494-targets Bmi1 and ADAM10 by silibinin and ablates cancer stemness in head and neck squamous cell carcinomas PMID: 26090866
49. These findings indicate that different mechanisms regulate shear- and ligand-induced shedding and shear forces found within the vasculature can regulate ADAM10 activity. PMID: 26840909
50. Data suggest that large extracellular loop of Tspan14 mediates interaction with ADAM10, promotes ADAM10 maturation/trafficking to cell surface, and affects ADAM10 substrate specificity; ADAM10/Tspan14 interact in platelets/vascular endothelial cells. PMID: 26668317

Show More

Hide All

HGNC: 188

OMIM: 602192

KEGG: hsa:102

STRING: 9606.ENSP00000260408

UniGene: Hs.172028